Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Jul 01, 2021 10:09am
216 Views
Post# 33478902

RE:Based on current results…..

RE:Based on current results…..Keytruda got approval with 19% CR at 12 months and more treatments and side effects.  Vicinium is waiting on FDA decision early August and has a 17% CR at 12 months after 36 instillations.  Anything above 20% would get us approved  after complete trial of 100 patients and we would be another very decent option IMO. Accelerated Approval would probably come if we hit 67% or better IMO and that may take another 15-20 optimally treated patients .  At 67% or better CR we would be a blockbuster drug treatment and capture a major share of the market.  All IMHO.  Time will tell. In a few weeks we may have data on another 3 patients and get a better picture.  I hope they treat another 5 or more very soon.
<< Previous
Bullboard Posts
Next >>